Skip to main content
Premium Trial:

Request an Annual Quote

Products: OGT's SureSeq Solid Tumor Panel


Oxford Gene Technologies has launched a targeted sequencing service for tumor profiling. The SureSeq Solid Tumor Panel service analyzes 58 cancer-related genes to detect novel and actionable mutations in breast, prostate, ovarian, lung, and colorectal cancers.

The panel was developed in collaboration with researchers from the University of Southampton, University of Birmingham, and CIS Healthcare as part of a £1.16 ($1.75) million funding award from UK's Technology Strategy Board's Stratified Medicines program.

Also included in the program was a panel launched by the University of Oxford earlier this year and a panel still in development by Source BioScience (CSN 1/2/2013).

OGT's panel uses Agilent's SureSelect hybridization technology and was validated on both fresh frozen and formalin-fixed, paraffin-embedded tissue against blinded, previously genotyped samples.